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ABSTRACT
Phytoestrogens, including miroestrol and deoxymiroestrol, have the ability to act
through competition with estrogen for binding to the estrogen receptor (ER). Here, we
utilize manual ligand docking followed by molecular dynamics simulations and binding
free energy calculations with the linear interaction energy method to predict the binding
modes and the binding affinities of phytoestrogens on the ligand binding domain of ER
(ER-LBD). The calculations brought about the good correlation between the
calculated binding free energy and the bioassays. Furthermore, consideration of
Lennard-Jones and Coulomb interaction energies of miroestrol and deoxymiroestrol on
ER-LBD provided the information to develop the phytoestrogen derivatives as the
preferred drug for ER positive breast cancer treatment.
INTRODUCTION
In Thailand, Pueraria mirifica, an indigenous herb belongs to the Family Leguminosae,
is considered to be a rejuvenating folk medicine. Pueraria mirifica contains
miroestrols, particularly miroestrol and deoxymiroestrol, which make difference to any
other phytoestrogen-containing plants in the Family Leguminosae [1-3]. Miroestrols
are an isoflavonoid compound which has the chemical structure similar to female
estrogenic hormones, estradiol [4]. However, unlike 17-estradiol, miroestrol and
deoxymiroestrol are not steroidal compounds. Chansakaow et al. isolated and
identified deoxymiroestrol from the root of Pueraria mirifica, and concluded that it is
more likely to be the actual chemical constituent of Pueraria mirifica because of its
facile aerial oxidization into miroestrol [5]. Other compounds found in Pueraria
mirifica that belong to isoflavone and coumestran groups of phytoestrogens are
Genistein, Daidzein, Daidzin, Genistin and Coumestrol.
Breast cancer occurs in both men and women, although male breast cancer is rare.
New cases and deaths from breast cancer in the United States in 2008 were estimated as
below; new cases: 182,460 (female); 1,990 (male), deaths: 40,480 (female); 450 (male)
(http://www.cancer.gov/cancertopics/types/breast). Interest in phytoestrogens has been
fueled by epidemiologic studies that have suggested low incidence of breast cancer in
countries with high soy intake. However, this has been followed by in vitro and in
vivo animal research suggesting a potential role for phytoestrogens in preventing breast
cancer development, the role of phytoestrogens in breast cancer remains controversial
[6]. Matsumura et al. have compared the estrogen agonist and antagonist activity of
eight phytoestrogens (genistein, daidzein, equol, miroestrol, deoxymiroestrol,
8-prenylnaringenin, coumestrol and resveratrol) in a range of assays all based within the
same receptor and cellular context of the MCF7 human breast cancer cell line [7].
In the present study, manual docking, molecular dynamics (MD) simulations and the
linear interaction energy (LIE) method are combined to predict binding modes and
estimate the binding free energies of protein-ligand interactions [8-11]. Therefore, we
attempted to establish in silico screening methodology for the development of
phytoestrogen derivatives as the preferred drug for ER positive breast cancer treatment
[12]. The predicted binding affinities of phytoestrogens on the ligand binding domain
of ER by in silico screening methodology were compared with the bioassay data of
Matsumura et al. [7]. Thus consideration of an ongoing need for breast cancer drugs
with greater efficacy and fewer side effects made us insight into estrogenicity of
phytoestrogens [13].
Materials and Methods
Preparation and MD Simulations of Estrogen Recptor/Ligand Complexes
Construction of the ligand binding domain of estrogen receptor alpha (ER-LBD) with
ligand complexes and subsequent molecular dynamics (MD) simulations were
performed as described before with some modifications [11]. Briefly, ER-LBD
(residues M294 to S554) was taken from the Protein Data Bank (PDB ID; 3ERD), and
then several optimizations prior to MD simulations were carried out by using Modeler
8.2 [14] and Reduce 2.21 [15]. For all ligands (17-estradiol, deoxymiroestrol,
miroestrol, 8-prenylnaringenin, genistein, coumestrol, equol, daidzein, raloxifene-core,
OBCP-1M and WAY-244), the force fields parameters were taken from the general
Amber force field (GAFF) [16], whereas the atomic partial charges were derived by
semi-empirical AM1 calculations with MOPAC2006 (Fujitsu Ltd., Japan), to which the
charges were fitted using the AM1-BCC procedure [17]. Ligands were placed in the
binding site of ER-LBD by manual docking (Figure 1) using CAChe 6.1 (Fujitsu Ltd.,
Japan). All MD simulations were carried out on ER-LBD/ligand complexes using
the GROMACS 3.3.1 [18] after minimization using MM2 force field in CAChe 6.1
(Fujitsu Ltd., Japan). The minimum distance between the complex and the boundaries
was 6 Å, resulting in typical box volume sizes of about 9.87 x 105 Å 3, and contained ca.
100,000 atoms including ER-LBD and ligand. Simulations of free ligands in water
were carried out under periodic boundary conditions with a minimum distance between
the ligand and the boundaries of 10 Å, resulting in a box volume of about 3.2 x 104 Å 3
with ca. 3,300 atoms. Stepwise heating (35ps), equilibration (750 ps) and subsequent
MD simulations (250 ps) were carried out as described for ER-LBD/ligand complexes
and free-ligands. Subsequently, the stepwise heating protocol was used to relax water
molecules in the systems [19].
The linear interaction energy Calculations
The linear interaction energy (LIE) method was used to calculate binding free energies
from the MD simulations [8-11]. Lennard-Jones (LJ) and Coulomb interaction
energies between the ligand and its environment were collected to obtain the values of
calculated binding free energy ( calcG ) during MD simulation. These energies were
averaged every 0.2 ps from the 250 ps production run. Subsequently, Binding free
energies ( iG ) were calculated for any orientation by
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Where
LJE and
CoulE denotes the LJ interaction energy and the Coulomb interaction
energy of the ligand bound to the receptor (BOUND) and the ligand free in solution
(FREE), respectively. The parameters =0.82 and =0.20 were used [11]. LJ
interactions were calculated using a twin-range cutoff.
Short-range interactions (within 11 Å) were evaluated every time step from a pair list
that was updated every 5 time steps. Longer-range interactions (within 12 Å) were
evaluated every 5 time steps as well and kept constant between updates. A long-range
correction for the finite cutoff of LJ potential was taken into account for energy and
pressure corrections, but not for the binding free energy afterward. The particle mesh
Ewald summation method was used for long-range electrostatic interactions [20].
RESULTS
Confirmation of Our Methodology
We attempted to confirm whether manual ligand docking followed by molecular
dynamics (MD) simulations and binding free energy calculations with the linear
interaction energy (LIE) method reproduces same binding mode with the
crystallographic structure of the ligands (17-estradiol; 3ERD, genistein; 1X7R,
raloxifene; 2JFA, OBCP-1M; 2B1V, WAY-244; 1X7E) that were complex with ligand
binding domain of ER alfa (ER-LBD) [8-11]. As shown in Figure 2 (A-E), the
orientation with the best interaction energy of them closely reproduced the
crystallographic structure of the protein-ligand complex. The RMSDs of each ligand
relative to that in the crystallographic structure of the protein-ligand complex were 0.26
Å for 17-estradiol, 0.31 Å for genistein, 0.21 Å for raloxifene core, 0.40 Å for
OBCP-1M and 0.25 Å for WAY-244. In the most cases, hydrogen bonding with E353,
R394, and H524 was observed for the orientation with the best interaction energy as
listed in Table 1. Analysis of the RMSD values of the heavy atoms of several selected
amino acid residues of the binding cavity (M343, L346, L349, A350, E353, L384, L387,
M388, L391, R394, F404, L424, G521, H524, L525) showed even smaller variations:
average RMSD = 0.98 ± 0.1 Å. This indicates that the orientation and conformation of
the amino acids directly involved in ligand binding was also well-preserved.
Prediction of Binding Structure by Our Methodology
We applied the manual docking, MD simulations and LIE methods on the prediction of
the binding mode and the interaction energy of structure unsolved miroestrols. Figure
2 (F-K) shows the binding mode with the best interaction energy of deoxymiroestrol,
miroestrol, 8-prenylnaringenin, coumestrol, equol and daidzein complex with
ER-LBD, respectively. These predicted structures were consistent with the binding
mode with structure-known ligands as shown in Figure 2 (F-K). For example, the OH
groups of six miroestrols were predicted to form hydrogen bond with E353 and H524.
Furthermore, all predicted binding modes of six miroestrols reproduced perpendicular
-stacking conformations of F404 and the aromatic moiety of a ligand which
contributes significantly to the binding energy [21]. Finally, hydrogen bonds through a
water molecule to E353 were presented.
Evaluation of Predicted Interaction Energies by Bioassays
To evaluate in silico screening methodology described in this study, we have plotted the
predicted interaction energies of phytoestrogens complex with ER-LBD against the
experimental agonist activity of them by Matsumura et al [7]. Figure 3 shows the
correlation of the interaction energy versus the estrogen-sensitive reporter gene assay
with an R2=0.79 (Figure 3A) and cell growth assay with an R2=0.86 (Figure 3B),
respectively [22].
Difference of Binding Affinity between Deoxymiroestrol and Miroestrol
To understand why deoxymiroestrol provides a significant increase in affinity and
antagonist potency compared to miroestrol, we performed the detail consideration of
Lennard-Jones (LJ) and Coulomb interaction energies between the ligand and its
environment. As summarized in Table 2A, the sum of contribution in bound state for
deoxymiroestrol of -38.5 kcal/mol is slightly stronger than that for miroestrol of -38.3
kcal/mol. On the other hand, the sum of penalty in free state for deoxymiroestrol of
-26.6 kcal/mol is weaker than that for miroestrol of -27.6kcal/mol (Table 2B).
Therefore, these results mean that the affinity of deoxymiroestrol on ER-LBD is 1.2
kcal/mol stronger than that of miroestrol.
DISCUSSION
The aim of this study is to establish in silico screening methodology for the
development of phytoestrogen derivatives as the preferred drug for ER positive breast
cancer treatment [19,23-25]. We have performed in silico screening consists of
manual ligand docking followed by MD simulations and binding free energy
calculations with LIE method for phytoestrogens on ER-LBD [8-11]. The predicted
binding affinities of phytoestrogens on ER-LBD by our in silico screening
methodology showed excellent correlation with the experiment data using a range of
assays all based within the same receptor and cellular context of the MCF7 human
breast cancer cell line by Matsumura et al. [7]. However, the profile of interaction
energy of miroestrol and deoxymiroestrol were in pretty well agreement, the remarkable
difference between them are only arising from the functional group at 14 positions.
Therefore, we focused on why the functional group at 14 position of deoxymiroestrol,
the highest activity of all estrogens of plant origin, plays a critical role for the binding
with ER-LBD. As the results of the calculation, the difference of contribution in
bound state shows the interactions of deoxymiroestrol to ER-LBD is stronger (0.2
kcal/mol) than that of miroestrol. On the other hand, the difference of penalty in free
state showed that deoxymiroestrol has lower affinity to water (1.0kcal/mol) as compared
with miroestrol. These results indicate the interaction between the functional group at
14 position of miroestrols, miroestrol and deoxymiroestrol, and water determined the
binding stability of ligand-receptor complex (Figure 4).
Finally, the facile aerial oxidation of deoxymiroestrol into miroestrol loses its highest
esrogenicity in all estrogens of plant origin. Therefore, in silico screening
methodology for the development of phytoestrogen derivatives may be a powerful tool
to develop the deoxymiroestrol derivatives as the preferred drug for ER positive breast
cancer treatment.
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Figure Legends
Figure 1. Schematic view of four ligand docking orientations used in the present study.
Example for 17-estradiol.
Figure 2. Overlay of X-ray and predicted poses of ligands on ER-LBD, (A)
17-estradiol , (B) genistein, (C) raloxifene core, (D) OBCP-1M, and (E) WAY-244.
Each predicted structures were fitted to the protein bound crystal structure merged into
the reference protein coordinates. The crystal structure of the ligand (red) is compared
to the average structure during MD simulations (CPK colors). Predicted pose of
ligands on ER-LBD, (F) Deoxymiroestrol, (G) Miroestrol, (H) 8-Prenylnaringenin, (I)
Coumestrol, (J) Equol and (K) Daidzein.
Figure 3. Comparison of the predicted free energy of binding versus experimental
agonist activity for the eight ligands. The X-axis value of panel A and B were derived
from ERE-CAT and cell proliferation assay, respectively.
Figure 4. Schematic presentation of the interaction of phytoestrogens on ER-LBD
(red) and solvent (blue). R=OH; deoxymiroestrol, R=H; miroestrol.
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Table 1. Overview of the Lennard-Jones (ELJ) and Coulomb (ECoul) Interaction Energy
Bound FreeLigand Orientation in
Figure 1 (i=) ELJ ECoul ELJ ECoul
Gi pi
1 -32.6 -21.4 -21.1 -28.0 -11.2 0.99
2 -34.8 -13.8 -8.4 0.01
3 -32.2 -21.4 -7.8 0.00
17-Oestradiol
4 -33.2 -18.1 -7.9 0.00
1 -31.3 -29.3 -18.3 -36.8 -9.1 0.69
2 -27.2 -25.4 -5.0 0.00
3 -29.4 -34.7 -8.6 0.30
Genistein
4 -28.2 -29.3 -6.6 0.01
1 -32.4 -24.9 -18.9 -34.4 -8.1 0.41
2 -31.7 -20.0 -7.5 0.15
3 -31.8 -22.5 -8.0 0.36
Raloxifene core
4 -31.5 -23.3 -7.1 0.09
1 -32.1 -20.2 -18.5 -30.0 -9.2 0.74
2 -31.0 -19.6 -8.2 0.13
3 -31.9 -15.1 -7.2 0.03OBCP-1M
4 -30.5 -16.9 -8.0 0.10
1 -28.2 -22.9 -16.7 -29.7 -9.1 0.69
2 -27.8 -21.5 -7.6 0.05
3 -27.0 -23.2 -8.1 0.12
WAY-244
4 -28.3 -22.1 -8.2 0.14
1 -40.0 -29.0 -21.4 -45.3 -12.0 0.98
2 -34.8 -32.9 -8.5 0.00
3 -36.8 -28.0 -9.1 0.01
Deoxymiroestrol
4 -37.1 -24.4 -8.7 0.00
1 -39.9 -29.1 -19.8 -56.7 -11.0 0.81
2 -37.0 -28.9 -8.5 0.01
3 -36.5 -37.6 -9.8 0.12
Miroestrol
4 -37.8 -29.9 -9.4 0.06
1 -40.4 -26.0 -23.9 -37.7 -11.2 0.75
2 -39.4 -19.7 -9.2 0.02
3 -39.7 -23.7 -10.2 0.13
8-Prenylnaringenin
4 -41.4 -15.3 -9.9 0.09
1 -28.6 -28.0 -18.4 -35.7 -6.8 0.15
2 -30.2 -23.4 -7.2 0.28
3 -28.5 -30.0 -7.2 0.27
Coumestrol
4 -29.7 -25.4 -7.2 0.29
1 -28.7 -28.8 -17.4 -32.6 -8.5 0.38
2 -29.9 -23.4 -8.4 0.33
3 -29.5 -24.6 -8.3 0.27
Equol
4 -26.8 -27.1 -6.6 0.02
1 -25.9 -25.8 -16.8 -39.4 -4.7 0.00
2 -28.6 -30.5 -7.9 0.60
3 -27.4 -33.8 -7.6 0.35
Daidzein
4 -28.2 -24.4 -6.4 0.05
All E and G values are given in kcal/mol.
Table
Table 2A. Energy contributions in bound states for calculated binding free energy of
deoxymiroestrol, miroestrol, and the difference. All units are kcal/mol.
Deoxymiroestrol Miroestrol
LJ
BOUNDE -32.7 -32.3
Coul
BOUNDE -5.8 -6.0
Coul
BOUND
LJ
BOUND EE   -38.5 -38.3
Table 2B. Energy contributions in free states for calculated binding free energy of
deoxymiroestrol, miroestrol, and the difference. All units are kcal/mol.
Deoxymiroestrol Miroestrol
LJ
FREEE -17.5 -16.3
Coul
FREEE -9.1 -11.3
Coul
FREE
LJ
FREE EE   -26.6 -27.6
Table
